Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TNF receptor-Fc fusion protein (TNFR-Fc)
OPRX-106 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| OPRX-106 | DRUG | - |
OPRX-106 is an investigational small molecule drug developed by Protalix BioTherapeutics, Inc. (ticker: PLX). It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease indications for which OPRX-106 is being developed have not been disclosed.
OPRX-106 is being developed by Protalix BioTherapeutics, Inc., a biopharmaceutical company that trades under the ticker symbol PLX. Protalix is the sponsor of the clinical program for OPRX-106.
OPRX-106 is in Phase 1 clinical development. One Phase 1 trial has been completed. There are currently no active trials of OPRX-106 listed. The drug remains investigational and has not been approved by the FDA for any indication.
OPRX-106 has been evaluated in one completed Phase 1 clinical trial, NCT02107833, titled "Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers." The trial enrolled 18 healthy volunteers and was an uncontrolled study.
No, OPRX-106 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. Approval would require successful completion of later-stage clinical trials and regulatory review.